[go: up one dir, main page]

US20150080998A1 - Magnesium-aluminum-zinc alloy, method for the production thereof and use thereof - Google Patents

Magnesium-aluminum-zinc alloy, method for the production thereof and use thereof Download PDF

Info

Publication number
US20150080998A1
US20150080998A1 US14/395,709 US201314395709A US2015080998A1 US 20150080998 A1 US20150080998 A1 US 20150080998A1 US 201314395709 A US201314395709 A US 201314395709A US 2015080998 A1 US2015080998 A1 US 2015080998A1
Authority
US
United States
Prior art keywords
weight
alloy
magnesium
content
equal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/395,709
Inventor
Heinz Mueller
Peter Uggowitzer
Joerg Loeffler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotronik AG
Original Assignee
Biotronik AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotronik AG filed Critical Biotronik AG
Priority to US14/395,709 priority Critical patent/US20150080998A1/en
Assigned to BIOTRONIK AG reassignment BIOTRONIK AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LOEFFLER, JOERG, DR., UGGOWITZER, PETER, DR., MUELLER, HEINZ, DR.
Publication of US20150080998A1 publication Critical patent/US20150080998A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02Inorganic materials
    • A61L27/04Metals or alloys
    • CCHEMISTRY; METALLURGY
    • C22METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22FCHANGING THE PHYSICAL STRUCTURE OF NON-FERROUS METALS AND NON-FERROUS ALLOYS
    • C22F1/00Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working
    • C22F1/06Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of magnesium or alloys based thereon
    • CCHEMISTRY; METALLURGY
    • C22METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22CALLOYS
    • C22C23/00Alloys based on magnesium
    • C22C23/02Alloys based on magnesium with aluminium as the next major constituent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00Preparations for dentistry
    • A61K6/80Preparations for artificial teeth, for filling teeth or for capping teeth
    • A61K6/84Preparations for artificial teeth, for filling teeth or for capping teeth comprising metals or alloys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02Inorganic materials
    • A61L27/04Metals or alloys
    • A61L27/047Other specific metals or alloys not covered by A61L27/042 - A61L27/045 or A61L27/06
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58Materials at least partially resorbable by the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/02Inorganic materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/02Inorganic materials
    • A61L31/022Metals or alloys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/148Materials at least partially resorbable by the body
    • CCHEMISTRY; METALLURGY
    • C22METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22CALLOYS
    • C22C23/00Alloys based on magnesium
    • C22C23/04Alloys based on magnesium with zinc or cadmium as the next major constituent

Definitions

  • a field of the invention relates to a magnesium alloy and to a method for the production thereof and to the use thereof.
  • Magnesium alloys of the invention are applicable to implants, including cardiovascular, osteosynthesis, and tissue implants.
  • Example applications include stents, valves, closure devices, occluders, clips, coils, staples, implantable regional drug delivery devices, implantable electrostimulators (like pacemakers and defibrillators), implantable monitoring devices, implantable electrodes, systems for fastening and temporarily fixing tissue implants and tissue transplantations.
  • Additional example applications include implantable plates, pins, rods, wires, screws, clips, nails, and staples.
  • Magnesium alloy properties are determined by the type and quantity of the alloying elements and impurities as well as the production conditions. The effects of the alloying elements and impurities on the properties of the magnesium alloys have been known to artisans. However, determining the properties of binary or ternary magnesium alloys for use as implant materials remains complex.
  • the alloying element used most frequently for magnesium is aluminum.
  • Aluminum provides increased tensile strength due to solid solution and precipitation hardening and fine grain formation, but also in microporosity. Moreover, in the melt aluminum shifts the iron precipitation boundary toward drastically lower iron contents at which the iron particles precipitate or form intermetallic particles together with other elements.
  • Undesirable accompanying elements in magnesium alloys include iron, nickel, cobalt and copper, which cause a considerable increase in the corrosion tendency due to the electropositive nature thereof.
  • Manganese can be found in all magnesium casting alloys and binds iron in the form of AlMnFe precipitations, whereby the formation of local elements is reduced. On the other hand, manganese is not able to bind all the iron, and therefore a remainder of iron and a remainder of manganese are always left in the melt.
  • Silicon lowers the castability and viscosity, and as the content of Si rises, a worsened corrosion behavior is to be expected.
  • Iron, manganese and silicon have a very high tendency to form an intermetallic phase.
  • the electrochemical potential of this phase is very high and can thus act as a cathode controlling the corrosion of the alloy matrix.
  • zirconium Alloying additions made of zirconium increase the tensile strength without lowering the expansion and lead to grain refining, but also to a strong impairment of dynamic recrystallization, which is manifested in an increase of the recrystallization temperature and therefore requires high energy expenditure. Moreover, zirconium cannot be added to melts containing aluminum and silicon because the grain refining effect is lost.
  • Rare earths such as Lu, Er, Ho, Th, Sc and In all exhibit a similar chemical behavior and form eutectic systems with partial solubility on the magnesium-rich side of the binary phase diagrams such that precipitation hardening is possible.
  • intermetallic phase Mg 17 Al 12 forming at the grain boundaries is brittle and limits the ductility.
  • this intermetallic phase is more noble and able to form local elements, whereby the corrosion behavior worsens.
  • the properties of the magnesium alloys also decisively depend on the metallurgical production conditions.
  • Conventional casting methods automatically introduce impurities when adding, by alloying, the alloying elements.
  • the prior art U.S. Pat. No. 5,055,254 A
  • tolerance limits for impurities in magnesium casting alloys which, for example for a magnesium-aluminum-zinc alloy containing approximately 8 to 9.5% by weight Al and 0.45 to 0.9% by weight Zn, mentions tolerance limits of 0.0015 to 0.0024% by weight Fe, 0.0010% by weight Ni, 0.0010 to 0.0024% by weight Cu and no less than 0.15 to 0.5% by weight Mn.
  • Biodegradable implants require a load-bearing function and consequently strength, together with sufficient expandability, during the physiologically necessary support periods thereof.
  • Known magnesium materials fall far short of the strength properties provided by permanent implants made from other materials such as titanium, CoCr alloys and titanium alloys.
  • the ultimate tensile strength R m for permanent implants is approximately 500 MPa to >1000 MPa, while that of magnesium materials is ⁇ 275 MPa so far, and in most cases ⁇ 250 MPa.
  • magnesium alloys can generally also form textures during forming processes such as extrusion, rolling and drawing used to produce suitable semifinished products by orienting the grains during the forming process. Specifically, this means that the semifinished product has different properties in different directions in space. For example, high deformability or elongation at fracture occurs in one direction in space after forming, and reduced deformability or elongation at fracture occurs in another direction in space.
  • the formation of such textures should likewise be avoided, because a stent is subjected to high plastic deformation, and reduced elongation at fracture increases the risk of failure of the implant.
  • One method for substantially avoiding such textures during forming is to adjust as fine a grain as possible prior to forming.
  • the ability of these materials to deform at room temperature is low, which is characterized by slip in the base plane.
  • the material additionally has a coarse microstructure, i.e., a coarse grain, so-called twinning is forcibly produced upon further deformation, at which shear strain occurs, which transforms a crystal region into a position that is mirror symmetrical to the starting position.
  • the resulting twin grain boundaries constitute weak points in the material, where incipient cracking starts, especially with plastic deformation, which ultimately leads to the destruction of the component.
  • Implant materials should therefore have as fine a grain as possible so as to prevent such undesirable shear strain.
  • All available magnesium materials for implants are subject to high corrosion in physiological media. Attempts have been made to curb the corrosion tendency by providing the implants with a corrosion-inhibiting coating, for example made of polymeric materials (EP 2 085 100 A2, EP 2 384 725 A1), an aqueous or alcoholic conversion solution (DE 10 2006 060 501 A1) or an oxide (DE 10 2010 027 532 A1, EP 0 295 397 A1).
  • a corrosion-inhibiting coating for example made of polymeric materials (EP 2 085 100 A2, EP 2 384 725 A1), an aqueous or alcoholic conversion solution (DE 10 2006 060 501 A1) or an oxide (DE 10 2010 027 532 A1, EP 0 295 397 A1).
  • Degradable magnesium alloys are especially suitable for implementing implants which have been employed in a wide variety of forms in modern medical technology. Implants are used, for example, to support vessels, hollow organs and vein systems (endovascular implants, such as stents), for fastening and temporarily fixing tissue implants and tissue transplantations, but also for orthopedic purposes, such as nails, plates or screws. A particularly frequently used form of an implant is the stent.
  • stents have the purpose of assuming a supporting function in hollow organs of a patient.
  • stents featuring conventional designs have a filigree supporting structure comprising metal struts, which is initially present in compressed form for introduction into the body and is expanded at the site of the application.
  • One of the main application areas of such stents is to permanently or temporarily widen and hold open vascular constrictions, particularly constrictions (stenosis) of coronary blood vessels.
  • aneurysm stents are known, which are used primarily to seal the aneurysm.
  • the support function is additionally provided.
  • a stent has a base body made of an implant material.
  • An implant material is a non-living material, which is employed for applications in medicine and interacts with biological systems.
  • biocompatibility shall be understood to mean the ability of a material to induce an appropriate tissue reaction in a specific application. This includes an adaptation of the chemical, physical, biological, and morphological surface properties of an implant to the recipient's tissue with the aim of a clinically desired interaction.
  • the biocompatibility of the implant material is also dependent on the temporal process of the reaction of the biosystem in which it is implanted.
  • the implant materials can be divided into bioactive, bioinert and degradable or resorbable materials.
  • Biocompatible metals and metal alloys for permanent implants include, for example, stainless steels (such as 316L), cobalt-based alloys (such as CoCrMo cast alloys, CoCrMo forge alloys, CoCrWNi forge alloys and CoCrNiMo forge alloys), pure titanium and titanium alloys (such as cp titanium, TiAl6V4 or TiAl6Nb7) and gold alloys.
  • stainless steels such as 316L
  • cobalt-based alloys such as CoCrMo cast alloys, CoCrMo forge alloys, CoCrWNi forge alloys and CoCrNiMo forge alloys
  • pure titanium and titanium alloys such as cp titanium, TiAl6V4 or TiAl6Nb7
  • gold alloys such as gold alloys.
  • Preferred embodiments of the invention provide a biodegradable magnesium alloy, a method for the production thereof and implants made from the alloy, which allow the magnesium matrix of the implant to remain in an electrochemically stable state over the required support period with fine grain and high corrosion resistance without protective layers, and to utilize the formation of intermetallic phases, which electrochemically are more noble than the magnesium matrix, while also improving the mechanical properties, such as increasing the tensile strength and proof stress, as well as reducing the mechanical asymmetry so as to adjust the degradation rate of the implants.
  • a preferred magnesium alloy includes less or equal to 4.0% by weight Zn, 2.0 to 10.0% by weight Al, wherein the alloy content of Al in % by weight is greater than or equal to the alloy content of Zn in % by weight, with the remainder being magnesium which contains impurities, which promote electrochemical potential differences and/or the formation of precipitations and/or intermetallic phases, in a total amount of no more than 0.0063% by weight of Fe, Si, Mn, Co, Ni, Cu, Zr, Y, Sc or rare earths having the ordinal numbers 21, 57 to 71 and 89 to 103, Be, Cd, In, Sn and/or Pb as well as P, wherein the matrix of the alloy is solid solution hardening due to Al and Zn and is also particle hardening due to the intermetallic phases formed of Mg and Al.
  • the magnesium alloy has a content of Zn less or equal 2.0% by weight, in particular preferably less or equal 1.0% by weight and/or a content of Al in the range of 2.0 to 8.0% by weight, preferably 3.0 to 8.0% by weight and still more preferably 3.0 to 6.0% by weight.
  • a preferred method of producing a magnesium alloy includes generating a high-purity magnesium by vacuum distillation.
  • a billet of the alloy is synthesized with the high-purity magnesium and with less or equal 4.0% by weight Zn, 2.0 to 10.0% by weight Al, wherein the alloy content of Al in % by weight is greater than or equal to the alloy content of Zn in % by weight, the remainder being magnesium containing impurities, which promote electrochemical potential differences and/or the formation of precipitations and/or intermetallic phases, in a total amount of no more than 0.0063% by weight of Fe, Si, Mn, Co, Ni, Cu, Zr, Y, Sc or rare earths having the ordinal numbers 21, 57 to 71 and 89 to 103, Be, Cd, In, Sn and/or Pb as well as P, wherein the matrix of the alloy is solid solution hardening due to Al and Zn and is also particle hardening due to the intermetallic phases formed of Mg and Al.
  • the alloy is homogenized by annealing
  • the magnesium alloy according to the invention has very high corrosion resistance, which is achieved by drastically reducing the content of impurities and the combinations thereof in the magnesium matrix, and by having only those alloying elements present which raise the electrochemical potential of the matrix such that the corrosion resistance of the alloy is considerably increased. Corrosion resistance and deformability of the magnesium matrix of an implant with an alloy of the invention can be assured over a support period such that the implant is able to absorb multiaxial permanent load without fracture or cracking, and the implant can also benefit from the magnesium matrix for decomposition triggered by the physiological liquids.
  • a corrosion-stable alloy matrix can be achieved when complying with the following tolerance limits of individual impurities in % by weight: Fe, Si, Mn, Co, Ni, Cu each with ⁇ 0.0005; Zr, Y each with ⁇ 0.0003; and P ⁇ 0.0002.
  • the alloy has additional individual impurities in the following tolerance limits (% by weight): Sc or rare earths having the ordinal numbers 21, 57 to 71 and 89 to 103 in total ⁇ 0.001; Be, Cd, In, Sn and/or Pb each with ⁇ 0.0003.
  • the corrosion-staple alloy matrix contains impurities in a total amount of no more than 0.0053 Gew. %, which can be achieved when complying with the following tolerance limits of individual impurities in % by weight:
  • the corrosion-staple alloy matrix contains impurities in a total amount of no more than 0.0022 Gew.%, which can be achieved when complying with the following tolerance limits of individual impurities in % by weight:n: Fe, Si, Mn each with ⁇ 0.0002; Co, Ni, Cu, Zr, Y each with ⁇ 0.0001; Sc or rare earths having the ordinal numbers 21, 57 to 71 and 89 to 103 in total ⁇ 0.0005; Be, Cd, In, Sn and/or Pb each with ⁇ 0.0001, and P ⁇ 0.0001.
  • this tolerance limit of the sum of impurities of Fe, Si, Mn, Co, Ni and Cu is no more than 0.003% by weight, preferably no more than 0.0021% by weight and in particular preferred no more than 0.0009% by weight.
  • Preferred magnesium alloys according to the present invention can achieve a tensile strength of >275 MPa, and preferably >300 MPa, a yield point of >200 MPa, and preferably >225 MPa, and a yield ratio of ⁇ 0.8, and preferably ⁇ 075, wherein the difference between the tensile strength and yield point is >50 MPa, and preferably >100 MPa, and the mechanical asymmetry is ⁇ 1.25.
  • the improved mechanical properties of the novel magnesium alloys assure that the implants, for example cardiovascular stents, are able to withstand the multiaxial permanent load in the implanted state over the entire support period, despite onsetting degradation of the magnesium matrix due to corrosion.
  • the magnesium alloy For the mechanical asymmetry, it is particularly important for the magnesium alloy to have a particularly fine microstructure having a grain size of no more than 7.5 ⁇ m, preferably ⁇ 5 ⁇ m, and still more preferably ⁇ 2.5 ⁇ m.
  • a preferred method for producing a magnesium alloy having the improved mechanical and electrochemical properties is also provided by the invention.
  • the method comprises the following steps:
  • steps c) and d) can be repeated at least once.
  • an ageing treatment step can be performed.
  • the alloy composition and/or the amount and/or type of the grains and/or the grain size ageing treatment step can be performed at a temperature between 20° C. and 300° C. with a holding period of 1 h to 168 h.
  • the ageing treatment can be performed at a temperature between 20° C. and 275° C., still more preferably at a temperature of 150° C. with a holding period of 120 hours.
  • steps c) is performed at a temperature between 250° C. and 450° C. and/or step d) is performed at a temperature between 225° C. and 400° C.
  • the magnesium alloy generated by step a) has a content of Zn less or equal 2.0% by weight, in particular preferably less or equal 1.0% by weight and/or a content of Al in the range of 2.0 to 8.0% by weight, preferably 3.0 to 8.0% by weight and still more preferably 3.0 to 6.0% by weight.
  • Vacuum distillation is preferably used to produce a starting material for a high-purity magnesium-aluminum-zinc alloy having the required threshold values.
  • the sum of impurities can be selectively adjusted and in % by weight are:
  • Extrusion, equal channel angular extrusion and/or multiple forging can thus preferably be employed, which assure that a substantially homogeneous fine grain of ⁇ 10 ⁇ m is achieved.
  • the magnesium alloy produced according to the method which has the above described advantageous composition and structure, in medical technology, can also be used in the production of implants, for example endovascular implants such as stents, for fastening and temporarily fixing tissue implants and tissue transplantations, orthopedic and dental implants, and neuroimplants.
  • implants for example endovascular implants such as stents, for fastening and temporarily fixing tissue implants and tissue transplantations, orthopedic and dental implants, and neuroimplants.
  • Particular implants of the invention are in the Cardiovascular field, osteosynthesis field or other areas.
  • a magnesium alloy is generated which is composed of 2.0% by weight Zn and 6.0% by weight Al, the remainder being Mg, and contains the following individual impurities in % by weight:
  • Fe ⁇ 0.0005; Si: ⁇ 0.0005; Mn: ⁇ 0.0005; Co: ⁇ 0.0002; Ni: ⁇ 0.0002; Cu ⁇ 0.0002, wherein the sum of impurities of Fe, Si, Mn, Co, Ni, Cu is no more than 0.0021% by weight and that of Zr is no more than 0.0003% by weight.
  • the magnesium produced with aid of vacuum distillation is melted with high-purity Al and Zn in a graphite crucible, and the alloy is subjected to homogenizing annealing at a temperature of 360° C. for a duration of 24 hours, and subsequently to multiple extrusion processes at a temperature of 300° C., so as to produce a precision tube for a cardiovascular stent.
  • the grain size of the microstructure was ⁇ 5.5 ⁇ m, and the particle size of the intermetallic phases dispersely distributed in the alloy matrix was 0.5 ⁇ m.
  • the magnesium alloy reached a tensile strength of 310 to 320 MPa and proof stress of approximately 250 MPa [sic].
  • the yield ratio was 0.79 and the mechanical asymmetry was 1.2.
  • a magnesium alloy is generated which is composed of 0.25% by weight Zn and 2.50% by weight Al, the remainder being Mg, and contains the following individual impurities in % by weight:
  • Fe ⁇ 0.0005; Si: ⁇ 0.0005; Mn: ⁇ 0.0005; Co: ⁇ 0.0002; Ni: ⁇ 0.0002; Cu ⁇ 0.0002, wherein the sum of impurities of Fe, Si, Mn, Co, Ni, Cu is no more than 0.0021% by weight and that of Zr is no more than 0.0003% by weight.
  • the magnesium produced with aid of vacuum distillation is melted with high-purity Al and Zn in a graphite crucible, and the alloy is subjected to homogenizing annealing at a temperature of 360° C. for a duration of 24 hours, and subsequently to multiple extrusion processes at a temperature of 300° C., so as to produce a precision tube for a cardiovascular stent.
  • the grain size of the microstructure was ⁇ 5.5 ⁇ m, and the particle size of the intermetallic phases dispersely distributed in the alloy matrix was 0.5 ⁇ m.
  • the magnesium alloy reached a tensile strength of 310 to 320 MPa and proof stress of approximately 250 MPa [sic].
  • the yield ratio was 0.79 and the mechanical asymmetry was 1.2.
  • a magnesium alloy is generated which is composed of 5.0% by weight Al, the remainder being Mg, and contains the following individual impurities in % by weight:
  • Fe ⁇ 0.0005; Si: ⁇ 0.0005; Mn: ⁇ 0.0005; Co: ⁇ 0.0002; Ni: ⁇ 0.0002; Cu ⁇ 0.0002, wherein the sum of impurities of Fe, Si, Mn, Co, Ni, Cu is no more than 0.0021% by weight and that of Zr is no more than 0.0003% by weight.
  • the magnesium produced with aid of vacuum distillation is melted with high-purity Al in a graphite crucible, and the alloy is subjected to homogenizing annealing at a temperature of 360° C. for a duration of 24 hours, and subsequently to multiple extrusion processes at a temperature of 300° C., so as to produce a precision tube for a cardiovascular stent.
  • the grain size of the microstructure was ⁇ 5.5 ⁇ m, and the particle size of the intermetallic phases dispersely distributed in the alloy matrix was 0.5 ⁇ m.
  • the magnesium alloy reached a tensile strength of 310 to 320 MPa and proof stress of approximately 250 MPa [sic].
  • the yield ratio was 0.79 and the mechanical asymmetry was 1.2.
  • a magnesium alloy is generated which is composed of 3% by weight Al, the remainder being Mg, and contains the following individual impurities in % by weight:
  • Fe ⁇ 0.0005; Si: ⁇ 0.0005; Mn: ⁇ 0.0005; Co: ⁇ 0.0002; Ni: ⁇ 0.0002; Cu ⁇ 0.0002, wherein the sum of impurities of Fe, Si, Mn, Co, Ni, Cu is no more than 0.0021% by weight and that of Zr is no more than 0.0003% by weight.
  • the magnesium produced with aid of vacuum distillation is melted with high-purity Al in a graphite crucible, and the alloy is subjected to homogenizing annealing at a temperature of 360° C. for a duration of 24 hours, and subsequently to multiple extrusion processes at a temperature of 300° C., so as to produce a precision tube for a cardiovascular stent.
  • the grain size of the microstructure was ⁇ 5.5 ⁇ m, and the particle size of the intermetallic phases dispersely distributed in the alloy matrix was 0.5 ⁇ m.
  • the magnesium alloy reached a tensile strength of 310 to 320 MPa and proof stress of approximately 250 MPa [sic].
  • the yield ratio was 0.79 and the mechanical asymmetry was 1.2.
  • a magnesium alloy is generated which is composed of 0.25% by weight Zn and 2.0% by weight Al, the remainder being Mg, and contains the following individual impurities in % by weight:
  • Fe ⁇ 0.0005; Si: ⁇ 0.0005; Mn: ⁇ 0.0005; Co: ⁇ 0.0002; Ni: ⁇ 0.0002; Cu ⁇ 0.0002, wherein the sum of impurities of Fe, Si, Mn, Co, Ni, Cu is no more than 0.0021% by weight and that of Zr is no more than 0.0003% by weight.
  • the magnesium produced with aid of vacuum distillation is melted with high-purity Al and Zn in a graphite crucible, and the alloy is subjected to homogenizing annealing at a temperature of 360° C. for a duration of 24 hours and thereafter to an ageing treatment at 125° C. for 120 hours.
  • the material is subjected to multiple extrusion processes at a temperature of 200° C., so as to produce a precision tube for a cardiovascular stent.
  • the grain size of the microstructure was ⁇ 5.5 ⁇ m, and the particle size of the intermetallic phases dispersely distributed in the alloy matrix was 0.5 ⁇ m.
  • the magnesium alloy reached a tensile strength of 320 to 350 MPa and proof stress of approximately 235 MPa.
  • the yield ratio was 0.70 and the mechanical asymmetry was 1.2.
  • a magnesium alloy is generated which is composed of 1.5% by weight Zn and 3.0% by weight Al, the remainder being Mg, and contains the following individual impurities in % by weight:
  • Fe ⁇ 0.0005; Si: ⁇ 0.0005; Mn: ⁇ 0.0005; Co: ⁇ 0.0002; Ni: ⁇ 0.0002; Cu ⁇ 0.0002, wherein the sum of impurities of Fe, Si, Mn, Co, Ni, Cu is no more than 0.0021% by weight and that of Zr is no more than 0.0003% by weight.
  • the magnesium produced with aid of vacuum distillation is melted with high-purity Al and Zn in a graphite crucible, and the alloy is subjected to homogenizing annealing at a temperature of 360° C. for a duration of 24 hours and thereafter to an ageing treatment at 150° C. for 120 hours.
  • the material is subjected to an extrusion process at a temperature of 200° C., so as to produce a rod with 8 mm diameter to produce screws for craniofacial fixations.
  • the grain size of the microstructure was ⁇ 3.0 ⁇ m, and the particle size of the intermetallic phases dispersely distributed in the alloy matrix was 0.5 ⁇ m.
  • the magnesium alloy reached a tensile strength of 340 to 360 MPa and proof stress of approximately 250 MPa [sic].
  • the yield ratio was 0.71 and the mechanical asymmetry was 1.2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Organic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Mechanical Engineering (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Thermal Sciences (AREA)
  • Cardiology (AREA)
  • Plastic & Reconstructive Surgery (AREA)
  • Materials For Medical Uses (AREA)
  • Manufacture Of Metal Powder And Suspensions Thereof (AREA)
  • Prostheses (AREA)
  • Powder Metallurgy (AREA)

Abstract

A magnesium alloy and to a method for the production thereof and implants made thereof. The magnesium alloy includes up to 6.0% by weight Zn, and preferably 2.0 to 4.0% by weight Zn, 2.0 to 10.0% by weight Al, and preferably 3.0 to 6.0% by weight Al, where % by weight Al≧% by weight Zn shall apply, the remainder being magnesium containing impurities, which promote electrochemical potential differences and/or the formation of precipitations and/or intermetallic phases, in a total amount of no more than 0.0063% by weight of Fe, Si, Mn, Co, Ni, Cu, Zr, Y, Sc or rare earths having the ordinal numbers 21, 57 to 71 and 89 to 103, Be, Cd, In, Sn and/or Pb as well as P, and the matrix of the alloy is solid solution hardening due to Al and An and is also particle hardening due to the intermetallic phases formed of Mg and Al.

Description

    PRIORITY CLAIM
  • This application is a U.S. National Phase under 35 U.S.C. §371 of International Application No. PCT/EP2013/063110, filed Jun. 24, 2013, which claims priority to U.S. Provisional Application No. 61/664,224, filed Jun. 26, 2012.
  • FIELD OF THE INVENTION
  • A field of the invention relates to a magnesium alloy and to a method for the production thereof and to the use thereof. Magnesium alloys of the invention are applicable to implants, including cardiovascular, osteosynthesis, and tissue implants. Example applications include stents, valves, closure devices, occluders, clips, coils, staples, implantable regional drug delivery devices, implantable electrostimulators (like pacemakers and defibrillators), implantable monitoring devices, implantable electrodes, systems for fastening and temporarily fixing tissue implants and tissue transplantations. Additional example applications include implantable plates, pins, rods, wires, screws, clips, nails, and staples.
  • BACKGROUND
  • Magnesium alloy properties are determined by the type and quantity of the alloying elements and impurities as well as the production conditions. The effects of the alloying elements and impurities on the properties of the magnesium alloys have been known to artisans. However, determining the properties of binary or ternary magnesium alloys for use as implant materials remains complex.
  • The alloying element used most frequently for magnesium is aluminum. Aluminum provides increased tensile strength due to solid solution and precipitation hardening and fine grain formation, but also in microporosity. Moreover, in the melt aluminum shifts the iron precipitation boundary toward drastically lower iron contents at which the iron particles precipitate or form intermetallic particles together with other elements.
  • Calcium exhibits a pronounced grain refining effect and worsens the castability and corrosion resistance.
  • Undesirable accompanying elements in magnesium alloys include iron, nickel, cobalt and copper, which cause a considerable increase in the corrosion tendency due to the electropositive nature thereof.
  • Manganese can be found in all magnesium casting alloys and binds iron in the form of AlMnFe precipitations, whereby the formation of local elements is reduced. On the other hand, manganese is not able to bind all the iron, and therefore a remainder of iron and a remainder of manganese are always left in the melt.
  • Silicon lowers the castability and viscosity, and as the content of Si rises, a worsened corrosion behavior is to be expected. Iron, manganese and silicon have a very high tendency to form an intermetallic phase. The electrochemical potential of this phase is very high and can thus act as a cathode controlling the corrosion of the alloy matrix.
  • As a result of solid solution hardening, zinc improves the mechanical properties and results in grain refining, however it also leads to microporosity with a tendency toward hot cracking starting at a content of 1.5 to 2% by weight in binary Mg—Zn and ternary Mg—Al—Zn alloys.
  • Alloying additions made of zirconium increase the tensile strength without lowering the expansion and lead to grain refining, but also to a strong impairment of dynamic recrystallization, which is manifested in an increase of the recrystallization temperature and therefore requires high energy expenditure. Moreover, zirconium cannot be added to melts containing aluminum and silicon because the grain refining effect is lost.
  • Rare earths such as Lu, Er, Ho, Th, Sc and In all exhibit a similar chemical behavior and form eutectic systems with partial solubility on the magnesium-rich side of the binary phase diagrams such that precipitation hardening is possible.
  • The addition of further alloying elements, in conjunction with the impurities, is known to cause the formation of different intermetallic phases in binary magnesium alloys. For example, the intermetallic phase Mg17Al12 forming at the grain boundaries is brittle and limits the ductility. As compared to the magnesium matrix, this intermetallic phase is more noble and able to form local elements, whereby the corrosion behavior worsens.
  • In addition to these influencing factors, the properties of the magnesium alloys also decisively depend on the metallurgical production conditions. Conventional casting methods automatically introduce impurities when adding, by alloying, the alloying elements. The prior art (U.S. Pat. No. 5,055,254 A) therefore defines tolerance limits for impurities in magnesium casting alloys, which, for example for a magnesium-aluminum-zinc alloy containing approximately 8 to 9.5% by weight Al and 0.45 to 0.9% by weight Zn, mentions tolerance limits of 0.0015 to 0.0024% by weight Fe, 0.0010% by weight Ni, 0.0010 to 0.0024% by weight Cu and no less than 0.15 to 0.5% by weight Mn.
  • Tolerance limits for impurities in magnesium and the alloys thereof as well as the production conditions are mentioned in many known documents and listed as follows in % by weight:
  • Alloy Production State Fe Fe/Mn Ni Cu
    Pure no information 0.017 0.005 0.01
    Mg
    AZ 91 Die casting F 0.032 0.005 0.040
    High-pressure die casting 0.032 0.005 0.040
    Low-pressure die casting 0.032 0.001 0.040
    T4 0.035 0.001 0.010
    T6 0.046 0.001 0.040
    Gravity die casting F 0.032 0.001 0.040
    AM60 Die casting F 0.021 0.003 0.010
    AM50 Die casting F 0.015 0.003 0.010
    AS41 Die casting F 0.010 0.004 0.020
    AE42 Die casting F 0.020 0.020 0.100
  • It has been found that these tolerance definitions are not sufficient to reliably exclude the formation of corrosion-promoting intermetallic phases, which in terms of electrochemistry have a more noble potential than the magnesium matrix.
  • Biodegradable implants require a load-bearing function and consequently strength, together with sufficient expandability, during the physiologically necessary support periods thereof. Known magnesium materials fall far short of the strength properties provided by permanent implants made from other materials such as titanium, CoCr alloys and titanium alloys. The ultimate tensile strength Rm for permanent implants is approximately 500 MPa to >1000 MPa, while that of magnesium materials is <275 MPa so far, and in most cases <250 MPa.
  • Another drawback of many prior magnesium materials is that the difference between ultimate tensile strength Rm and proof stress Rp is small. In the case of implants that allow plastic deformation, such as cardiovascular stents, this means that no further resistance exists against deformation after initial deformation of the material, and the regions that have already been deformed are deformed further without any load increase. This can lead to overstretching of parts of the component and fracture may occur.
  • Many magnesium materials additionally exhibit a clearly pronounced mechanical asymmetry, which is manifested in the difference in the mechanical properties, especially the proof stress Rp with tension load and compression load. Such asymmetries are created, for example, during forming processes such as extrusion, rolling and drawing, which are used to produce suitable semi-finished products. A difference between the proof stress Rp during tension and the proof stress Rp during compression that is too large may result in inhomogeneous deformation of a component, such as a cardiovascular stent, which later undergoes multiaxial deformation, and may cause cracking and fracture.
  • Because of the low number of crystallographic slip systems, magnesium alloys can generally also form textures during forming processes such as extrusion, rolling and drawing used to produce suitable semifinished products by orienting the grains during the forming process. Specifically, this means that the semifinished product has different properties in different directions in space. For example, high deformability or elongation at fracture occurs in one direction in space after forming, and reduced deformability or elongation at fracture occurs in another direction in space. The formation of such textures should likewise be avoided, because a stent is subjected to high plastic deformation, and reduced elongation at fracture increases the risk of failure of the implant. One method for substantially avoiding such textures during forming is to adjust as fine a grain as possible prior to forming. Because of the hexagonal lattice structure of magnesium materials, the ability of these materials to deform at room temperature is low, which is characterized by slip in the base plane. If the material additionally has a coarse microstructure, i.e., a coarse grain, so-called twinning is forcibly produced upon further deformation, at which shear strain occurs, which transforms a crystal region into a position that is mirror symmetrical to the starting position. The resulting twin grain boundaries constitute weak points in the material, where incipient cracking starts, especially with plastic deformation, which ultimately leads to the destruction of the component.
  • If the grain of the implant materials is sufficiently fine, the risk of such implant failure is drastically reduced. Implant materials should therefore have as fine a grain as possible so as to prevent such undesirable shear strain.
  • All available magnesium materials for implants are subject to high corrosion in physiological media. Attempts have been made to curb the corrosion tendency by providing the implants with a corrosion-inhibiting coating, for example made of polymeric materials (EP 2 085 100 A2, EP 2 384 725 A1), an aqueous or alcoholic conversion solution (DE 10 2006 060 501 A1) or an oxide (DE 10 2010 027 532 A1, EP 0 295 397 A1).
  • The polymeric passivation layers are controversial, because virtually all appropriate polymers also cause strong inflammations in the tissue at times. On the other hand, thin magnesium alloy structures without such protective measures do not resist corrosions for the required support periods. The corrosion on thin-walled traumatological implants is often times accompanied by an excessively fast loss of tensile strength, which poses an additional burden by forming excessive amounts of hydrogen per unit of time. The consequences are undesirable gas inclusions in the bones and tissue. In the case of traumatological implants having larger cross-sections, there is a need to be able to deliberately control the hydrogen problem and the corrosion rate of the implant by way of the structure thereof.
  • Specifically with biodegradable implants, there is a desire for maximum biocompatibility of the elements, because all the chemical elements that are contained are absorbed by the body after decomposition. In any case, highly toxic elements such as Be, Cd, Pb, Cr and the like should be avoided.
  • Degradable magnesium alloys are especially suitable for implementing implants which have been employed in a wide variety of forms in modern medical technology. Implants are used, for example, to support vessels, hollow organs and vein systems (endovascular implants, such as stents), for fastening and temporarily fixing tissue implants and tissue transplantations, but also for orthopedic purposes, such as nails, plates or screws. A particularly frequently used form of an implant is the stent.
  • The implantation of stents has become established as one of the most effective therapeutic measures for the treatment of vascular diseases. Stents have the purpose of assuming a supporting function in hollow organs of a patient. For this purpose, stents featuring conventional designs have a filigree supporting structure comprising metal struts, which is initially present in compressed form for introduction into the body and is expanded at the site of the application. One of the main application areas of such stents is to permanently or temporarily widen and hold open vascular constrictions, particularly constrictions (stenosis) of coronary blood vessels. In addition, aneurysm stents are known, which are used primarily to seal the aneurysm. The support function is additionally provided.
  • A stent has a base body made of an implant material. An implant material is a non-living material, which is employed for applications in medicine and interacts with biological systems. A basic prerequisite for the use of a material as an implant material, which is in contact with the body environment when used as intended, is biocompatibility. For the purpose of the present application, biocompatibility shall be understood to mean the ability of a material to induce an appropriate tissue reaction in a specific application. This includes an adaptation of the chemical, physical, biological, and morphological surface properties of an implant to the recipient's tissue with the aim of a clinically desired interaction. The biocompatibility of the implant material is also dependent on the temporal process of the reaction of the biosystem in which it is implanted. For example, irritations and inflammations occur in a relatively short time, which can lead to tissue changes. Depending on the properties of the implant material, biological systems thus react in different ways. According to the reaction of the biosystem, the implant materials can be divided into bioactive, bioinert and degradable or resorbable materials.
  • Conventional implant materials include polymers, metallic materials, and ceramic materials (as coatings, for example). Biocompatible metals and metal alloys for permanent implants include, for example, stainless steels (such as 316L), cobalt-based alloys (such as CoCrMo cast alloys, CoCrMo forge alloys, CoCrWNi forge alloys and CoCrNiMo forge alloys), pure titanium and titanium alloys (such as cp titanium, TiAl6V4 or TiAl6Nb7) and gold alloys. In the field of biocorrodible stents, the use of magnesium or pure iron as well as biocorrodible base alloys of the elements magnesium, iron, zinc, molybdenum, and tungsten have been proposed.
  • The use of biocorrodible magnesium alloys for temporary implants having filigree structures is made difficult in particular because degradation of the implant progresses very quickly in vivo. So as to reduce the corrosion rate, i.e., the degradation speed, different approaches are being discussed in the art. Modified alloys and coatings represent categories of approaches to reduce the corrosion rate of magnesium alloys. Some of the existing approaches show promise, but none of them has so far led to a commercially available product to the knowledge of the inventors. Regardless of the efforts made so far, there remains a need for solutions to at least temporarily reduce the corrosion of magnesium alloys in vivo, while optimizing the mechanical properties thereof at the same time.
  • SUMMARY OF THE INVENTION
  • Preferred embodiments of the invention provide a biodegradable magnesium alloy, a method for the production thereof and implants made from the alloy, which allow the magnesium matrix of the implant to remain in an electrochemically stable state over the required support period with fine grain and high corrosion resistance without protective layers, and to utilize the formation of intermetallic phases, which electrochemically are more noble than the magnesium matrix, while also improving the mechanical properties, such as increasing the tensile strength and proof stress, as well as reducing the mechanical asymmetry so as to adjust the degradation rate of the implants.
  • A preferred magnesium alloy includes less or equal to 4.0% by weight Zn, 2.0 to 10.0% by weight Al, wherein the alloy content of Al in % by weight is greater than or equal to the alloy content of Zn in % by weight, with the remainder being magnesium which contains impurities, which promote electrochemical potential differences and/or the formation of precipitations and/or intermetallic phases, in a total amount of no more than 0.0063% by weight of Fe, Si, Mn, Co, Ni, Cu, Zr, Y, Sc or rare earths having the ordinal numbers 21, 57 to 71 and 89 to 103, Be, Cd, In, Sn and/or Pb as well as P, wherein the matrix of the alloy is solid solution hardening due to Al and Zn and is also particle hardening due to the intermetallic phases formed of Mg and Al.
  • Preferably, the magnesium alloy has a content of Zn less or equal 2.0% by weight, in particular preferably less or equal 1.0% by weight and/or a content of Al in the range of 2.0 to 8.0% by weight, preferably 3.0 to 8.0% by weight and still more preferably 3.0 to 6.0% by weight.
  • A preferred method of producing a magnesium alloy includes generating a high-purity magnesium by vacuum distillation. A billet of the alloy is synthesized with the high-purity magnesium and with less or equal 4.0% by weight Zn, 2.0 to 10.0% by weight Al, wherein the alloy content of Al in % by weight is greater than or equal to the alloy content of Zn in % by weight, the remainder being magnesium containing impurities, which promote electrochemical potential differences and/or the formation of precipitations and/or intermetallic phases, in a total amount of no more than 0.0063% by weight of Fe, Si, Mn, Co, Ni, Cu, Zr, Y, Sc or rare earths having the ordinal numbers 21, 57 to 71 and 89 to 103, Be, Cd, In, Sn and/or Pb as well as P, wherein the matrix of the alloy is solid solution hardening due to Al and Zn and is also particle hardening due to the intermetallic phases formed of Mg and Al. The alloy is homogenized by annealing at a temperature between 150° C. and 450° C. with a holding period of 4 to 40 hours. The homogenized alloy is formed in the temperature range between 200° C. and 400° C.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • The magnesium alloy according to the invention has very high corrosion resistance, which is achieved by drastically reducing the content of impurities and the combinations thereof in the magnesium matrix, and by having only those alloying elements present which raise the electrochemical potential of the matrix such that the corrosion resistance of the alloy is considerably increased. Corrosion resistance and deformability of the magnesium matrix of an implant with an alloy of the invention can be assured over a support period such that the implant is able to absorb multiaxial permanent load without fracture or cracking, and the implant can also benefit from the magnesium matrix for decomposition triggered by the physiological liquids.
  • The previously known tolerance limits for impurities do not take into account that wrought magnesium alloys often times are subjected to a thermomechanical treatment, and more particularly to an extended annealing process, which creates the near-equilibrium structures. The metallic elements bond by way of diffusion and form what are known as intermetallic phases, which have a different electrochemical potential, notably a considerably higher potential, than the magnesium matrix, and therefore these intermetallic phases act as cathodes and can trigger galvanic corrosion processes.
  • The applicant has found that a corrosion-stable alloy matrix can be achieved when complying with the following tolerance limits of individual impurities in % by weight: Fe, Si, Mn, Co, Ni, Cu each with <0.0005; Zr, Y each with <0.0003; and P<0.0002. Further preferred in this embodiment, the alloy has additional individual impurities in the following tolerance limits (% by weight): Sc or rare earths having the ordinal numbers 21, 57 to 71 and 89 to 103 in total <0.001; Be, Cd, In, Sn and/or Pb each with <0.0003.
  • Preferably, the corrosion-staple alloy matrix contains impurities in a total amount of no more than 0.0053 Gew. %, which can be achieved when complying with the following tolerance limits of individual impurities in % by weight:
  • Fe, Si, Mn each with <0.0005; Co, Ni, Cu each with <0.0002; Zr, Y each with <0.0003; Sc or rare earths having the ordinal numbers 21, 57 to 71 and 89 to 103 in total <0.001; Be, Cd, In, Sn and/or Pb each with <0.0003; and P<0.0001.
  • In particular preferred embodiments, the corrosion-staple alloy matrix contains impurities in a total amount of no more than 0.0022 Gew.%, which can be achieved when complying with the following tolerance limits of individual impurities in % by weight:n: Fe, Si, Mn each with <0.0002; Co, Ni, Cu, Zr, Y each with <0.0001; Sc or rare earths having the ordinal numbers 21, 57 to 71 and 89 to 103 in total <0.0005; Be, Cd, In, Sn and/or Pb each with <0.0001, and P<0.0001.
  • It is surprising that the addition of manganese as an alloying element, which is customary in the prior art, can be dispensed with when these tolerance limits are adhered. The formation of the ternary intermetallic phase FeMnSi is suppressed, whereby the corrosion resistance of the alloy is improved.
  • When the impurity elements are combined, this tolerance limit of the sum of impurities of Fe, Si, Mn, Co, Ni and Cu is no more than 0.003% by weight, preferably no more than 0.0021% by weight and in particular preferred no more than 0.0009% by weight.
  • Preferred magnesium alloys according to the present invention can achieve a tensile strength of >275 MPa, and preferably >300 MPa, a yield point of >200 MPa, and preferably >225 MPa, and a yield ratio of <0.8, and preferably <075, wherein the difference between the tensile strength and yield point is >50 MPa, and preferably >100 MPa, and the mechanical asymmetry is <1.25.
  • These significantly improved mechanical properties can be attributed to the formation of solid solutions between aluminum and zinc in the alloy matrix as well as to the intermetallic phases of magnesium and aluminum occurring in the matrix. The basis for the increased tensile strength is the interaction of the dislocations with the particles, whereby the dislocation movement is adversely impacted and additional tension is required in order to generate the same plastic deformation as in an undisturbed matrix.
  • The improved mechanical properties of the novel magnesium alloys assure that the implants, for example cardiovascular stents, are able to withstand the multiaxial permanent load in the implanted state over the entire support period, despite onsetting degradation of the magnesium matrix due to corrosion.
  • For the mechanical asymmetry, it is particularly important for the magnesium alloy to have a particularly fine microstructure having a grain size of no more than 7.5 μm, preferably <5 μm, and still more preferably <2.5 μm.
  • A preferred method for producing a magnesium alloy having the improved mechanical and electrochemical properties is also provided by the invention. The method comprises the following steps:
    • a) generating high-purity magnesium by vacuum distillation;
    • b) generating a billet of the alloy by synthesis of the magnesium according to step a) with less or equal 4.0% by weight Zn, 2.0 to 10.0% by weight Al, wherein the alloy content of Al in % by weight is greater than or equal to the alloy content of Zn in % by weight, the remainder being magnesium containing impurities, which promote electrochemical potential differences and/or the formation of precipitations and/or intermetallic phases, in a total amount of no more than 0.0063% by weight of Fe, Si, Mn, Co, Ni, Cu, Zr, Y, Sc or rare earths having the ordinal numbers 21, 57 to 71 and 89 to 103, Be, Cd, In, Sn and/or Pb as well as P, wherein the matrix of the alloy is solid solution hardening due to Al and Zn and is also particle hardening due to the intermetallic phases formed of Mg and Al;
    • c) homogenizing the alloy by annealing at a temperature between 150° C. and 450° C. with a holding period of 4 to 40 hours; and
    • d) forming the homogenized alloy in the temperature range between 200° C. and 400° C.
  • Preferably steps c) and d) can be repeated at least once.
  • After step c) and before step d) an ageing treatment step can be performed. Depending on the alloy composition and/or the amount and/or type of the grains and/or the grain size ageing treatment step can be performed at a temperature between 20° C. and 300° C. with a holding period of 1 h to 168 h. Preferably the ageing treatment can be performed at a temperature between 20° C. and 275° C., still more preferably at a temperature of 150° C. with a holding period of 120 hours.
  • In a preferred value range steps c) is performed at a temperature between 250° C. and 450° C. and/or step d) is performed at a temperature between 225° C. and 400° C.
  • Preferably, the magnesium alloy generated by step a) has a content of Zn less or equal 2.0% by weight, in particular preferably less or equal 1.0% by weight and/or a content of Al in the range of 2.0 to 8.0% by weight, preferably 3.0 to 8.0% by weight and still more preferably 3.0 to 6.0% by weight.
  • Vacuum distillation is preferably used to produce a starting material for a high-purity magnesium-aluminum-zinc alloy having the required threshold values.
  • The sum of impurities can be selectively adjusted and in % by weight are:
    • a) for the individual impurities:
      • Fe, Si, Mn, Co, Ni, Cu each with <0.0005;
      • Zr, Y each with <0.0003; and
      • P<0.0002.
      • Preferably in this embodiment additional individual impurities in the following tolerance limits (% by weight):
      • Sc or rare earths having the ordinal numbers 21, 57 to 71 and 89 to 103 in total <0.001; Be, Cd, In, Sn and/or Pb each with <0.0003.
      • aa) for the individual impurities in a preferred total amount of impurities of no more than 0.0053% by weight:
        • Fe, Si, Mn each with <0.0005;
        • Co, Ni, Cu each with <0.0002;
        • Zr, Y each with <0.0003;
        • Sc or rare earths having the ordinal numbers 21, 57 to 71 and 89 to 103 in total <0.001;
        • Be, Cd, In, Sn and/or Pb each with <0.0003; and
        • P<0.0001.
      • ab) for the individual impurities in a particularly preferred total amount of impurities of no more than 0.0022% by weight:
        • Fe, Si, Mn each with <0.0002;
        • Co, Ni, Cu, Zr, Y each with <0.0001;
        • Sc or rare earths having the ordinal numbers 21, 57 to 71 and 89 to 103 in total <0.0005;
        • Be, Cd, In, Sn and/or Pb each with <0.0001; and
        • P<0.0001.
    • b) for the combination of individual impurities in total:
      • Fe, Si, Mn, Co, Ni, Cu no more than 0.003, preferably no more than 0.0021% by weight and in particular preferred no more than 0.0009% by weight.
  • It is particularly advantageous that the preferred method only requires a small number of forming steps. Extrusion, equal channel angular extrusion and/or multiple forging can thus preferably be employed, which assure that a substantially homogeneous fine grain of <10 μm is achieved.
  • The magnesium alloy produced according to the method, which has the above described advantageous composition and structure, in medical technology, can also be used in the production of implants, for example endovascular implants such as stents, for fastening and temporarily fixing tissue implants and tissue transplantations, orthopedic and dental implants, and neuroimplants.
  • Particular implants of the invention are in the Cardiovascular field, osteosynthesis field or other areas.
  • Cardiovascular field in the sense of this application includes
      • the field of diagnostic, prevention and treatment of all diseases of the cardiovascular system, i.e. heart and blood vessel system,
      • by mean of active and non-active implants used to support vessels, and vein systems
      • including coronary, cerebral and peripheral vascular implants like stents, valves, closure devices, occluders, clips, coils, staples, implantable regional drug delivery devices,
      • implantable electrostimulators (like pacemakers and defibrillators), implantable monitoring devices, implantable electrodes,
      • system for fastening and temporarily fixing tissue implants and tissue transplantations
      • field also includes any type of stent as mechanical fix or temporary scaffold to support hollow organs and structures including bones, intervertebral disks
  • Osteosynthesis in the sense of this application includes
      • the field of treatment of fractured bones for internal fixation and stabilization by mechanical devices such as metal plates, pins, rods, wires, screws, clips, nails, staples excluding stent technology
  • Examples of areas out of the osteosynthesis field or the cardiovascular field are:
      • Devices for the treatment of diseases of the sinews, joints, muscles, cartilages,
      • oral (including dental) and maxillo facial implants (excl. osteosynthesis means),
      • esthetic implants,
      • supporting tools out of the body,
      • tissue engineering,
      • soft tissue implants,
      • devices for wound care,
      • suture material and clamps,
      • neurosurgery
      • local drug delivery (excl. cardiovascular, i.e. lever)
      • renal
    Exemplary Embodiment 1
  • A magnesium alloy is generated which is composed of 2.0% by weight Zn and 6.0% by weight Al, the remainder being Mg, and contains the following individual impurities in % by weight:
  • Fe: <0.0005; Si: <0.0005; Mn: <0.0005; Co: <0.0002; Ni: <0.0002; Cu<0.0002, wherein the sum of impurities of Fe, Si, Mn, Co, Ni, Cu is no more than 0.0021% by weight and that of Zr is no more than 0.0003% by weight.
  • The magnesium produced with aid of vacuum distillation is melted with high-purity Al and Zn in a graphite crucible, and the alloy is subjected to homogenizing annealing at a temperature of 360° C. for a duration of 24 hours, and subsequently to multiple extrusion processes at a temperature of 300° C., so as to produce a precision tube for a cardiovascular stent.
  • The grain size of the microstructure was <5.5 μm, and the particle size of the intermetallic phases dispersely distributed in the alloy matrix was 0.5 μm.
  • The magnesium alloy reached a tensile strength of 310 to 320 MPa and proof stress of approximately 250 MPa [sic]. The yield ratio was 0.79 and the mechanical asymmetry was 1.2.
  • Exemplary Embodiment 2
  • A magnesium alloy is generated which is composed of 0.25% by weight Zn and 2.50% by weight Al, the remainder being Mg, and contains the following individual impurities in % by weight:
  • Fe: <0.0005; Si: <0.0005; Mn: <0.0005; Co: <0.0002; Ni: <0.0002; Cu<0.0002, wherein the sum of impurities of Fe, Si, Mn, Co, Ni, Cu is no more than 0.0021% by weight and that of Zr is no more than 0.0003% by weight.
  • The magnesium produced with aid of vacuum distillation is melted with high-purity Al and Zn in a graphite crucible, and the alloy is subjected to homogenizing annealing at a temperature of 360° C. for a duration of 24 hours, and subsequently to multiple extrusion processes at a temperature of 300° C., so as to produce a precision tube for a cardiovascular stent.
  • The grain size of the microstructure was <5.5 μm, and the particle size of the intermetallic phases dispersely distributed in the alloy matrix was 0.5 μm.
  • The magnesium alloy reached a tensile strength of 310 to 320 MPa and proof stress of approximately 250 MPa [sic]. The yield ratio was 0.79 and the mechanical asymmetry was 1.2.
  • Exemplary Embodiment 3
  • A magnesium alloy is generated which is composed of 5.0% by weight Al, the remainder being Mg, and contains the following individual impurities in % by weight:
  • Fe: <0.0005; Si: <0.0005; Mn: <0.0005; Co: <0.0002; Ni: <0.0002; Cu<0.0002, wherein the sum of impurities of Fe, Si, Mn, Co, Ni, Cu is no more than 0.0021% by weight and that of Zr is no more than 0.0003% by weight.
  • The magnesium produced with aid of vacuum distillation is melted with high-purity Al in a graphite crucible, and the alloy is subjected to homogenizing annealing at a temperature of 360° C. for a duration of 24 hours, and subsequently to multiple extrusion processes at a temperature of 300° C., so as to produce a precision tube for a cardiovascular stent.
  • The grain size of the microstructure was <5.5 μm, and the particle size of the intermetallic phases dispersely distributed in the alloy matrix was 0.5 μm.
  • The magnesium alloy reached a tensile strength of 310 to 320 MPa and proof stress of approximately 250 MPa [sic]. The yield ratio was 0.79 and the mechanical asymmetry was 1.2.
  • Exemplary Embodiment 4
  • A magnesium alloy is generated which is composed of 3% by weight Al, the remainder being Mg, and contains the following individual impurities in % by weight:
  • Fe: <0.0005; Si: <0.0005; Mn: <0.0005; Co: <0.0002; Ni: <0.0002; Cu<0.0002, wherein the sum of impurities of Fe, Si, Mn, Co, Ni, Cu is no more than 0.0021% by weight and that of Zr is no more than 0.0003% by weight.
  • The magnesium produced with aid of vacuum distillation is melted with high-purity Al in a graphite crucible, and the alloy is subjected to homogenizing annealing at a temperature of 360° C. for a duration of 24 hours, and subsequently to multiple extrusion processes at a temperature of 300° C., so as to produce a precision tube for a cardiovascular stent.
  • The grain size of the microstructure was <5.5 μm, and the particle size of the intermetallic phases dispersely distributed in the alloy matrix was 0.5 μm.
  • The magnesium alloy reached a tensile strength of 310 to 320 MPa and proof stress of approximately 250 MPa [sic]. The yield ratio was 0.79 and the mechanical asymmetry was 1.2.
  • Exemplary Embodiment 5
  • A magnesium alloy is generated which is composed of 0.25% by weight Zn and 2.0% by weight Al, the remainder being Mg, and contains the following individual impurities in % by weight:
  • Fe: <0.0005; Si: <0.0005; Mn: <0.0005; Co: <0.0002; Ni: <0.0002; Cu<0.0002, wherein the sum of impurities of Fe, Si, Mn, Co, Ni, Cu is no more than 0.0021% by weight and that of Zr is no more than 0.0003% by weight.
  • The magnesium produced with aid of vacuum distillation is melted with high-purity Al and Zn in a graphite crucible, and the alloy is subjected to homogenizing annealing at a temperature of 360° C. for a duration of 24 hours and thereafter to an ageing treatment at 125° C. for 120 hours.
  • Subsequently, the material is subjected to multiple extrusion processes at a temperature of 200° C., so as to produce a precision tube for a cardiovascular stent.
  • Before the final extrusion step is applied another annealing process is performed at 150° C. for 3 hours.
  • The grain size of the microstructure was <5.5 μm, and the particle size of the intermetallic phases dispersely distributed in the alloy matrix was 0.5 μm.
  • The magnesium alloy reached a tensile strength of 320 to 350 MPa and proof stress of approximately 235 MPa. The yield ratio was 0.70 and the mechanical asymmetry was 1.2.
  • Exemplary Embodiment 6
  • A magnesium alloy is generated which is composed of 1.5% by weight Zn and 3.0% by weight Al, the remainder being Mg, and contains the following individual impurities in % by weight:
  • Fe: <0.0005; Si: <0.0005; Mn: <0.0005; Co: <0.0002; Ni: <0.0002; Cu<0.0002, wherein the sum of impurities of Fe, Si, Mn, Co, Ni, Cu is no more than 0.0021% by weight and that of Zr is no more than 0.0003% by weight.
  • The magnesium produced with aid of vacuum distillation is melted with high-purity Al and Zn in a graphite crucible, and the alloy is subjected to homogenizing annealing at a temperature of 360° C. for a duration of 24 hours and thereafter to an ageing treatment at 150° C. for 120 hours.
  • Subsequently, the material is subjected to an extrusion process at a temperature of 200° C., so as to produce a rod with 8 mm diameter to produce screws for craniofacial fixations.
  • The grain size of the microstructure was <3.0 μm, and the particle size of the intermetallic phases dispersely distributed in the alloy matrix was 0.5 μm.
  • The magnesium alloy reached a tensile strength of 340 to 360 MPa and proof stress of approximately 250 MPa [sic]. The yield ratio was 0.71 and the mechanical asymmetry was 1.2.
  • While specific embodiments of the present invention have been shown and described, it should be understood that other modifications, substitutions and alternatives are apparent to one of ordinary skill in the art. Such modifications, substitutions and alternatives can be made without departing from the spirit and scope of the invention, which should be determined from the appended claims.
  • Various features of the invention are set forth in the appended claims.

Claims (21)

1. A magnesium alloy having improved mechanical and electrochemical properties, comprising: less or equal 4.0% by weight Zn, 2.0 to 10.0% by weight Al, the alloy content of Al in % by weight being greater than or equal to the alloy content of Zn in % by weight, the remainder being magnesium containing impurities, which promote electrochemical potential differences and/or the formation of precipitations and/or intermetallic phases, in a total amount of no more than 0.0063% by weight of Fe, Si, Mn, Co, Ni, Cu, Zr, Y, Sc or rare earths having the ordinal numbers 21, 57 to 71 and 89 to 103, Be, Cd, In, Sn and/or Pb as well as P, wherein the matrix of the alloy is solid solution hardening due to Al and Zn and is also particle hardening due to the intermetallic phases formed of Mg and Al.
2. The magnesium alloy according to claim 1, wherein the content of Zn less or equal 2.0% by weight, in particular preferably less or equal 1.0% by weight and/or the content of Al is 2.0 to 8.0% by weight, preferably 3.0 to 8.0% by weight and still more preferably 3.0 to 6.0% by weight.
3. The magnesium alloy according to claim 1, wherein individual impurities in the total sum of impurities amount to the following in % by weight: Fe, Si, Mn, Ni, Co, Cu each with <0.0005; Zr; Y each with <0.0003; and P<0.0002.
4. The magnesium alloy according to claim 1, wherein impurity elements Fe, Si, Mn, Co, Ni, and Cu together total no more than 0.003% by weight.
5. The magnesium alloy according to claim 1, wherein the alloy has a fine-grained microstructure having a grain size of no more than 7.5 μm.
6. The magnesium alloy according to claim 1, having a tensile strength of >275 MPa, a yield point of >200 MPa, and a yield ratio of <0.8, wherein the difference between the tensile strength and yield point is >50 MPa, and the mechanical asymmetry is <1.25.
7. A method for producing a magnesium alloy having improved mechanical and electrochemical properties, comprising:
a) generating a high-purity magnesium by vacuum distillation;
b) generating a billet of the alloy by synthesis of the high-purity magnesium with less or equal 4.0% by weight Zn, 2.0 to 10.0% by weight Al, wherein the alloy content of Al in % by weight is greater than or equal to the alloy content of Zn in % by weight, the remainder being magnesium containing impurities, which promote electrochemical potential differences and/or the formation of precipitations and/or intermetallic phases, in a total amount of no more than 0.0063% by weight of Fe, Si, Mn, Co, Ni, Cu, Zr, Y, Sc or rare earths having the ordinal numbers 21, 57 to 71 and 89 to 103, Be, Cd, In, Sn and/or Pb as well as P, wherein the matrix of the alloy is solid solution hardening due to Al and Zn and is also particle hardening due to the intermetallic phases formed of Mg and Al;
c) homogenizing the alloy by annealing at a temperature between 150° C. and 450° C. with a holding period of 4 to 40 hours;
d) forming of the homogenized alloy in the temperature range between 200° C. and 400° C.
8. The method according to claim 7, wherein the billet content of Zn is less or equal 2.0% by weight, and/or the content of Al is 2.0 to 8.0% by weight.
9. The method according to claim 7, wherein individual impurities in the total sum of impurities amount to the following in % by weight: Fe, Si, Mn, Ni, Co, Cu each with <0.0005; Zr, Y each with <0.0003; and P<0.0002.
10. The method according to claim 7, wherein Fe, Si, Mn, Co, Ni, and Cu together total no more than 0.003% by weight.
11. The method according to claim 7, wherein the forming process comprises extrusion, equal channel angular extrusion (EACE) and/or a multiple forging process.
12. The method according to claim 7, wherein steps c) and d) are repeated at least once.
13. The method according to claim 7, wherein step c) is performed at a temperature between 250° C. and 450° C. and/or step d) is performed at a temperature between 225° C. and 400° C.
14. A biodegradable implant formed from the alloy of claim 1.
15. A biodegradable implant according to claim 14, comprising one of a stent, an implant for fastening and temporarily fixing tissue implants and tissue transplantations, an orthopedic implant, a dental implant, and a neuroimplant.
16. (canceled)
17. (canceled)
18. The magnesium alloy according to claim 1, wherein the alloy has a fine-grained microstructure having a grain size of <5 μm.
19. The magnesium alloy according to claim 1, wherein the alloy has a fine-grained microstructure having a grain size of <2.5 μm.
20. The magnesium alloy according to claim 1, having a tensile strength of >300 MPa, a yield point of >225 MPa, and a yield ratio of <0.75, wherein the difference between the tensile strength and yield point is >100 MPa, and the mechanical asymmetry is <1.25.
21. The method according to claim 7, wherein the billet content of Zn is less or equal 1.0% by weight and/or the content of Al is 3.0 to 6.0% by weight.
US14/395,709 2012-06-26 2013-06-24 Magnesium-aluminum-zinc alloy, method for the production thereof and use thereof Abandoned US20150080998A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/395,709 US20150080998A1 (en) 2012-06-26 2013-06-24 Magnesium-aluminum-zinc alloy, method for the production thereof and use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261664224P 2012-06-26 2012-06-26
US14/395,709 US20150080998A1 (en) 2012-06-26 2013-06-24 Magnesium-aluminum-zinc alloy, method for the production thereof and use thereof
PCT/EP2013/063110 WO2014001240A1 (en) 2012-06-26 2013-06-24 Magnesium-aluminum-zinc alloy, method for the production thereof and use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/063110 A-371-Of-International WO2014001240A1 (en) 2012-06-26 2013-06-24 Magnesium-aluminum-zinc alloy, method for the production thereof and use thereof

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US15/933,635 Continuation US10995398B2 (en) 2012-06-26 2018-03-23 Corrosion resistant stent
US17/185,521 Division US12123086B2 (en) 2012-06-26 2021-02-25 Method for producing magnesium alloy
US18/883,519 Division US20250003044A1 (en) 2012-06-26 2024-09-12 Method for producing magnesium alloy

Publications (1)

Publication Number Publication Date
US20150080998A1 true US20150080998A1 (en) 2015-03-19

Family

ID=48672636

Family Applications (4)

Application Number Title Priority Date Filing Date
US14/395,709 Abandoned US20150080998A1 (en) 2012-06-26 2013-06-24 Magnesium-aluminum-zinc alloy, method for the production thereof and use thereof
US15/933,635 Active 2033-12-29 US10995398B2 (en) 2012-06-26 2018-03-23 Corrosion resistant stent
US17/185,521 Active 2033-10-08 US12123086B2 (en) 2012-06-26 2021-02-25 Method for producing magnesium alloy
US18/883,519 Pending US20250003044A1 (en) 2012-06-26 2024-09-12 Method for producing magnesium alloy

Family Applications After (3)

Application Number Title Priority Date Filing Date
US15/933,635 Active 2033-12-29 US10995398B2 (en) 2012-06-26 2018-03-23 Corrosion resistant stent
US17/185,521 Active 2033-10-08 US12123086B2 (en) 2012-06-26 2021-02-25 Method for producing magnesium alloy
US18/883,519 Pending US20250003044A1 (en) 2012-06-26 2024-09-12 Method for producing magnesium alloy

Country Status (13)

Country Link
US (4) US20150080998A1 (en)
EP (2) EP3896181A1 (en)
JP (2) JP6768295B2 (en)
KR (1) KR102246887B1 (en)
CN (2) CN109022976A (en)
AU (1) AU2013283536B2 (en)
BR (1) BR112014032641B1 (en)
CA (1) CA2867773C (en)
ES (1) ES2913105T3 (en)
HK (1) HK1200879A1 (en)
RU (2) RU2754035C2 (en)
SG (1) SG11201406021PA (en)
WO (1) WO2014001240A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150119995A1 (en) * 2012-06-26 2015-04-30 Biotronik Ag Magnesium alloy, method for the production thereof and use thereof
US9119906B2 (en) * 2008-09-24 2015-09-01 Integran Technologies, Inc. In-vivo biodegradable medical implant
WO2018187756A1 (en) * 2017-04-07 2018-10-11 The Board Of Trustees Of The University Of Illinois Bioresorbable magnesium-based sponge and foam materials, methods and devices
US20180363146A1 (en) * 2017-06-14 2018-12-20 Heraeus Deutschland GmbH & Co. KG Method for manufacturing a passivated product
US10344365B2 (en) 2012-06-26 2019-07-09 Biotronik Ag Magnesium-zinc-calcium alloy and method for producing implants containing the same
US10358709B2 (en) 2012-06-26 2019-07-23 Biotronik Ag Magnesium-zinc-calcium alloy, method for production thereof, and use thereof
US10995398B2 (en) 2012-06-26 2021-05-04 Biotronik Ag Corrosion resistant stent
US20220008625A1 (en) * 2019-03-28 2022-01-13 Japan Medical Device Technology Co., Ltd. Implant for non-luminal area
US11389308B2 (en) * 2014-11-28 2022-07-19 Biotyx Medical (Shenzhen) Co. Ltd. Lumen stent and preform thereof, and methods for preparing lumen stent and preform thereof
US11668015B2 (en) * 2016-05-04 2023-06-06 E2Metrix Inc. Magnesium-based alloy and use of same in the production of electrodes and the electrochemical synthesis of struvite
US11697869B2 (en) 2020-01-22 2023-07-11 Heraeus Deutschland GmbH & Co. KG Method for manufacturing a biocompatible wire

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9603728B2 (en) 2013-02-15 2017-03-28 Boston Scientific Scimed, Inc. Bioerodible magnesium alloy microstructures for endoprostheses
WO2015066181A1 (en) 2013-10-29 2015-05-07 Boston Scientific Scimed, Inc. Bioerodible magnesium alloy microstructures for endoprostheses
EP2992925B1 (en) 2014-09-04 2022-09-07 BIOTRONIK SE & Co. KG Intravascular electrode lead and intravascular stimulation device including the same
CA2973155A1 (en) 2015-03-11 2016-09-15 Boston Scientific Scimed, Inc. Bioerodible magnesium alloy microstructures for endoprostheses
CN105886804B (en) * 2016-05-16 2017-10-17 扬州大学 A kind of preparation method of high-performance Mg-Zn based alloy
DE102016119227A1 (en) * 2016-10-10 2018-04-12 Cortronik GmbH Bioresorbable extruded powder implants of varying chemical composition
KR101888091B1 (en) * 2016-10-31 2018-08-14 유앤아이 주식회사 Biodegradable Mg alloy and method of fabricating the same
CN106854723A (en) * 2016-12-09 2017-06-16 李晓光 A kind of high plastic magnesium alloy at room temperature
KR102200984B1 (en) * 2018-12-06 2021-01-11 금오공과대학교 산학협력단 Magnesium alloy for insert die casting, extruded material, and method of manufacturing the same
KR102210236B1 (en) * 2018-12-14 2021-02-01 울산과학기술원 Magnesium alloy materials and method for producing the same
CN109778037B (en) * 2019-03-14 2020-07-28 广西大学 Antibacterial magnesium alloy orthopedic material and preparation method thereof
CN109908408A (en) * 2019-03-18 2019-06-21 何煜冰 A kind of preparation method and application of the pure Zinc material of human body degradable biological
CN111228577A (en) * 2020-01-15 2020-06-05 太原科技大学 Medical magnesium alloy capable of being degraded in short term and preparation method thereof
WO2022152586A1 (en) 2021-01-15 2022-07-21 Biotronik Se & Co. Kg Implantable medical device
WO2022152587A1 (en) 2021-01-15 2022-07-21 Biotronik Se & Co. Kg Medical implant, particularly in form of an implantable intracardiac pacemaker, comprising a rotatable anchoring device to allow extraction of the encapsulated medical implant
WO2022152585A1 (en) 2021-01-15 2022-07-21 Biotronik Se & Co. Kg Implantable medical device
WO2022152470A1 (en) 2021-01-15 2022-07-21 Biotronik Se & Co. Kg A medical implant anchoring element with improved characteristics for implantation and retention
CN115637362B (en) * 2022-10-20 2024-04-16 西安交通大学 Water-soluble magnesium alloy and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101948957A (en) * 2010-10-14 2011-01-19 宁波翔博机械有限公司 Vacuum distillation method for magnesium alloy
US9561308B2 (en) * 2010-06-25 2017-02-07 Fort Wayne Metal Research Products Corporation Biodegradable composite wire for medical devices

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320055A (en) 1964-08-19 1967-05-16 Dow Chemical Co Magnesium-base alloy
SU557116A1 (en) * 1973-03-22 1977-05-05 Ордена Трудового Красного Знамени Березниковский Титано-Магниевый Комбинат Magnesium based alloy
CH672417A5 (en) 1987-06-17 1989-11-30 Sulzer Ag
SU1502648A1 (en) * 1987-10-16 1989-08-23 Казахский политехнический институт им.В.И.Ленина Alloy based on magnesium for tyre treades
JPH0247238A (en) 1988-08-08 1990-02-16 Nippon Telegr & Teleph Corp <Ntt> High-damping alloy and its production
US5055254A (en) 1989-10-05 1991-10-08 Timminco Limited Magnesium-aluminum-zinc alloy
JP3204572B2 (en) 1993-06-30 2001-09-04 株式会社豊田中央研究所 Heat resistant magnesium alloy
US5582630A (en) * 1995-02-21 1996-12-10 Sony Corporation Ultra high purity magnesium vacuum distillation purification method
KR970070222A (en) 1996-04-25 1997-11-07 박병재 Magnesium alloy for high pressure casting
RU2098506C1 (en) 1996-06-06 1997-12-10 Ольга Васильевна Деткова Magnesium-base alloy
KR19980702359A (en) * 1997-08-20 1998-07-15 터그럴 야사르 Ultra high purity magnesium and vacuum distillation purification method and apparatus
RU2198234C2 (en) * 2001-02-09 2003-02-10 Государственное предприятие Всероссийский научно-исследовательский институт авиационных материалов Magnesium-based alloy and article made from this alloy
AU2002950563A0 (en) 2002-08-02 2002-09-12 Commonwealth Scientific And Industrial Research Organisation Age-Hardenable, Zinc-Containing Magnesium Alloys
WO2005108634A1 (en) 2004-05-10 2005-11-17 Norsk Hydro Technology B.V. Magnesium alloy having improved elevated temperature performance
CN1743486A (en) 2004-08-31 2006-03-08 唐智荣 Alloy as magnesium element as matrix and its use as bone-fracture internal fixer
JP4730601B2 (en) * 2005-03-28 2011-07-20 住友電気工業株式会社 Magnesium alloy plate manufacturing method
EP1959025B1 (en) 2005-11-16 2012-03-21 National Institute for Materials Science Magnesium-based biodegradable metal material
CN100368028C (en) 2005-12-22 2008-02-13 上海交通大学 Bioabsorbable Mg-Zn Binary Magnesium Alloy Materials
CN1792383A (en) 2005-12-22 2006-06-28 上海交通大学 Bio-absorbable Mg-Zn-Ca three-elements magnesium alloy material
DE102006015457A1 (en) 2006-03-31 2007-10-04 Biotronik Vi Patent Ag Magnesium alloy and related manufacturing process
JP5429702B2 (en) 2006-08-03 2014-02-26 独立行政法人物質・材料研究機構 Magnesium alloy and manufacturing method thereof
ES2547011T3 (en) 2006-09-22 2015-09-30 U & I Corporation Implants comprising biodegradable metals and their manufacturing process
DE102006060501A1 (en) * 2006-12-19 2008-06-26 Biotronik Vi Patent Ag Forming corrosion-inhibiting anodized coating on bio-corrodible magnesium alloy implant, treats implant in aqueous or alcoholic solution containing specified ion concentration
AU2007202131A1 (en) 2007-05-14 2008-12-04 Joka Buha Method of heat treating magnesium alloys
DE102008006455A1 (en) 2008-01-29 2009-07-30 Biotronik Vi Patent Ag Implant comprising a body made of a biocorrodible alloy and a corrosion-inhibiting coating
KR101289122B1 (en) 2008-03-18 2013-07-23 한국보건산업진흥원 COMPLEX IMPLANTS INFILTERATED WITH BIODEGRADABLE Mg(ALLOYS) INSIDE POROUS STRUCTURAL MATERIALS AND METHOD FOR MANUFACTURING THE SAME
CN102046821B (en) 2008-06-03 2013-03-27 独立行政法人物质·材料研究机构 Mg-base alloy
JP5467294B2 (en) 2008-06-05 2014-04-09 独立行政法人産業技術総合研究所 Easy-formable magnesium alloy sheet and method for producing the same
US20110192500A1 (en) 2008-06-06 2011-08-11 Synthes Usa, Llc Resorbable magnesium alloy
CN101629260A (en) 2008-07-18 2010-01-20 中国科学院金属研究所 Medical absorbable Mg-Zn-Mn-Ca magnesium alloy
JP5432909B2 (en) * 2008-09-29 2014-03-05 テルモ株式会社 In-vivo stent and stent delivery system
JP5515167B2 (en) * 2008-10-28 2014-06-11 独立行政法人産業技術総合研究所 Commercial magnesium alloy sheet with improved room temperature formability and method for producing the same
JP5336204B2 (en) * 2009-01-13 2013-11-06 株式会社神戸製鋼所 Magnesium alloy with excellent balance between anisotropy and yield strength
US9347123B2 (en) 2009-01-19 2016-05-24 National Institute For Materials Science Mg-base alloy
KR20100106137A (en) * 2009-03-23 2010-10-01 주식회사 지알로이테크놀로지 Mg-zn base wrought magnesium alloys having superior formability at a high strain rate and low temperature and manufacturing method of the alloy sheet
CN102548589A (en) 2009-04-22 2012-07-04 友和安股份公司 Biodegradable implant and method for its preparation
CN101658691B (en) * 2009-07-31 2013-03-13 哈尔滨工业大学 Method for plastically manufacturing high-purity magnesium alloy absorbable stent
NZ599548A (en) * 2009-10-30 2013-04-26 Acrostak Corp Bvi Tortola Biodegradable implantable medical devices formed from super - pure magnesium-based material
US20130131814A1 (en) 2009-12-07 2013-05-23 Ja-Kyo Koo Implant
KR101470052B1 (en) 2009-12-07 2014-12-11 유앤아이 주식회사 Magnesium alloy
KR101405079B1 (en) 2010-03-17 2014-06-10 도쿠리츠교세이호징 붓시쯔 자이료 겐큐키코 Magnesium alloy
JP5939372B2 (en) * 2010-03-30 2016-06-22 住友電気工業株式会社 Coil material and manufacturing method thereof
US9072618B2 (en) 2010-05-06 2015-07-07 Biotronik Ag Biocorrodable implant in which corrosion may be triggered or accelerated after implantation by means of an external stimulus
RU2437949C1 (en) 2010-06-23 2011-12-27 Учреждение Российской академии наук Институт металлургии и материаловедения им. А.А. Байкова РАН Cast composite material on base of magnesium alloy and procedure for its manufacture
AT510087B1 (en) 2010-07-06 2012-05-15 Ait Austrian Institute Of Technology Gmbh MAGNESIUM ALLOY
CN102312144A (en) 2010-07-07 2012-01-11 乐普(北京)医疗器械股份有限公司 Ultrafine-grain medical magnesium alloy and preparation method thereof
DE102010027532B8 (en) 2010-07-16 2014-09-18 Aap Biomaterials Gmbh Process for PEO coating
CN101899600B (en) 2010-08-13 2012-04-25 上海交通大学 Orthopedic magnesium alloy implant material and preparation method thereof
JP5720926B2 (en) 2010-10-12 2015-05-20 住友電気工業株式会社 Magnesium alloy wire, bolt, nut and washer
US8956403B2 (en) 2010-10-18 2015-02-17 Boston Scientific Scimed, Inc. Medical implant including a magnesium-based tie layer
DE102011011344B4 (en) 2011-02-16 2014-12-11 Audi Ag Circuit arrangement for an electric seat heating
RU2618018C2 (en) 2012-01-19 2017-05-02 Етх Цюрих Process and apparatus for vacuum distillation of high-purity magnesium
US10895000B2 (en) 2012-06-26 2021-01-19 Biotronik Ag Magnesium alloy, method for the production thereof and use thereof
CA2869459C (en) 2012-06-26 2023-01-03 Biotronik Ag Magnesium-zinc-calcium alloy, method for production thereof, and use thereof
WO2014001240A1 (en) 2012-06-26 2014-01-03 Biotronik Ag Magnesium-aluminum-zinc alloy, method for the production thereof and use thereof
CN109097649A (en) 2012-06-26 2018-12-28 百多力股份公司 Magnesium alloy, its manufacturing method and application thereof
US9469889B2 (en) 2012-08-31 2016-10-18 DePuy Synthes Products, Inc. Ultrapure magnesium alloy with adjustable degradation rate
CN105143483B (en) 2013-03-14 2017-11-10 德普伊新特斯产品公司 Magnesium alloy with adjustable degradation rate
US9593397B2 (en) 2013-03-14 2017-03-14 DePuy Synthes Products, Inc. Magnesium alloy with adjustable degradation rate
US9398945B2 (en) 2013-09-19 2016-07-26 Cook Medical Technologies Llc Vascular implant retrieval assembly and method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9561308B2 (en) * 2010-06-25 2017-02-07 Fort Wayne Metal Research Products Corporation Biodegradable composite wire for medical devices
CN101948957A (en) * 2010-10-14 2011-01-19 宁波翔博机械有限公司 Vacuum distillation method for magnesium alloy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CN 891 Wang 10165A, listed as a foreign patent document in IDS filed on 8/24/2017, with on-line English translation, thereafter *
NPL: Machine translation of CN 10165891A, 03-2010 *
NPL-1: Kannan et al, Evaluating the stress corrosion cracking susceptibility of Mg-Al-Zn alloy in modified-simulated body fluid for orthopaedic implant application, Scripta Materialia, 59 (2008) 175-178. *
Numano PG 997 US 2012/0128 A1, thereafter *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10286120B2 (en) 2008-09-24 2019-05-14 Integran Technologies, Inc. In-vivo biodegradable medical implant comprising a microstructure engineered metallic material
US9119906B2 (en) * 2008-09-24 2015-09-01 Integran Technologies, Inc. In-vivo biodegradable medical implant
US10995398B2 (en) 2012-06-26 2021-05-04 Biotronik Ag Corrosion resistant stent
US12123086B2 (en) 2012-06-26 2024-10-22 Biotronik Ag Method for producing magnesium alloy
US10344365B2 (en) 2012-06-26 2019-07-09 Biotronik Ag Magnesium-zinc-calcium alloy and method for producing implants containing the same
US10358709B2 (en) 2012-06-26 2019-07-23 Biotronik Ag Magnesium-zinc-calcium alloy, method for production thereof, and use thereof
US10895000B2 (en) * 2012-06-26 2021-01-19 Biotronik Ag Magnesium alloy, method for the production thereof and use thereof
US20150119995A1 (en) * 2012-06-26 2015-04-30 Biotronik Ag Magnesium alloy, method for the production thereof and use thereof
US11499214B2 (en) 2012-06-26 2022-11-15 Biotronik Ag Magnesium-zinc-calcium alloy and method for producing implants containing the same
US11389308B2 (en) * 2014-11-28 2022-07-19 Biotyx Medical (Shenzhen) Co. Ltd. Lumen stent and preform thereof, and methods for preparing lumen stent and preform thereof
US11668015B2 (en) * 2016-05-04 2023-06-06 E2Metrix Inc. Magnesium-based alloy and use of same in the production of electrodes and the electrochemical synthesis of struvite
WO2018187756A1 (en) * 2017-04-07 2018-10-11 The Board Of Trustees Of The University Of Illinois Bioresorbable magnesium-based sponge and foam materials, methods and devices
US20180363146A1 (en) * 2017-06-14 2018-12-20 Heraeus Deutschland GmbH & Co. KG Method for manufacturing a passivated product
US20220008625A1 (en) * 2019-03-28 2022-01-13 Japan Medical Device Technology Co., Ltd. Implant for non-luminal area
US12251498B2 (en) * 2019-03-28 2025-03-18 Japan Medical Device Technology Co., Ltd. Implant for non-luminal area
US11697869B2 (en) 2020-01-22 2023-07-11 Heraeus Deutschland GmbH & Co. KG Method for manufacturing a biocompatible wire

Also Published As

Publication number Publication date
BR112014032641B1 (en) 2022-09-20
CN109022976A (en) 2018-12-18
US20210198778A1 (en) 2021-07-01
SG11201406021PA (en) 2014-10-30
HK1200879A1 (en) 2015-08-14
KR102246887B1 (en) 2021-05-03
AU2013283536B2 (en) 2018-03-01
US12123086B2 (en) 2024-10-22
CN104245983A (en) 2014-12-24
JP2019019412A (en) 2019-02-07
BR112014032641A2 (en) 2017-06-27
JP2015524512A (en) 2015-08-24
US10995398B2 (en) 2021-05-04
RU2017138372A (en) 2019-02-11
JP7053404B2 (en) 2022-04-12
CA2867773C (en) 2022-10-25
WO2014001240A1 (en) 2014-01-03
CA2867773A1 (en) 2014-01-03
RU2754035C2 (en) 2021-08-25
RU2015101291A (en) 2016-08-10
EP2864513A1 (en) 2015-04-29
US20250003044A1 (en) 2025-01-02
KR20150032933A (en) 2015-03-31
JP6768295B2 (en) 2020-10-14
EP2864513B1 (en) 2022-02-23
ES2913105T3 (en) 2022-05-31
US20180223406A1 (en) 2018-08-09
RU2017138372A3 (en) 2021-03-03
AU2013283536A1 (en) 2014-10-09
EP3896181A1 (en) 2021-10-20

Similar Documents

Publication Publication Date Title
US12123086B2 (en) Method for producing magnesium alloy
US10358709B2 (en) Magnesium-zinc-calcium alloy, method for production thereof, and use thereof
US10895000B2 (en) Magnesium alloy, method for the production thereof and use thereof
US11499214B2 (en) Magnesium-zinc-calcium alloy and method for producing implants containing the same
HK40007406A (en) Magnesium alloy, method for the production thereof and use thereof
HK1200880B (en) Magnesium-zinc-calcium alloy, method for production thereof, and use thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: BIOTRONIK AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MUELLER, HEINZ, DR.;UGGOWITZER, PETER, DR.;LOEFFLER, JOERG, DR.;SIGNING DATES FROM 20120621 TO 20120623;REEL/FRAME:033984/0222

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCV Information on status: appeal procedure

Free format text: NOTICE OF APPEAL FILED

STCV Information on status: appeal procedure

Free format text: APPEAL BRIEF (OR SUPPLEMENTAL BRIEF) ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: TC RETURN OF APPEAL

STCV Information on status: appeal procedure

Free format text: EXAMINER'S ANSWER TO APPEAL BRIEF MAILED

STCV Information on status: appeal procedure

Free format text: ON APPEAL -- AWAITING DECISION BY THE BOARD OF APPEALS

STCV Information on status: appeal procedure

Free format text: BOARD OF APPEALS DECISION RENDERED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION